Literature DB >> 20868665

Characterisation of P2X receptors expressed in rat pulmonary arteries.

Nawazish-i-Husain Syed1, Asrin Tengah, Andrew Paul, Charles Kennedy.   

Abstract

Previous studies indicated that a P2X receptor other than the P2X1 subtype might be present in rat large, but not small pulmonary arteries. The aim here was to characterise further these P2X receptors. Isometric tension was recorded from rat isolated small (i.d. 250-500 μm) and large pulmonary artery (i.d. 1-1.5 mm) rings mounted on a wire myograph. In both tissues the P2X receptor agonist α,β-meATP evoked rapidly-developing contractions that were inhibited by the P2X antagonists NF449, PPADS and suramin in a concentration-dependent manner and eventually abolished by each. The rank order of the potency in both tissues was NF449>PPADS=suramin. For each antagonist there was no significant difference between its potency in the small and large pulmonary arteries. Prolonged administration of a high concentration of α,β-meATP induced complete desensitisation in both tissues. RT-PCR followed by PCR with specific oligonucleotide primers, identified mRNA for all seven P2X subunits. Subtype-specific antibodies showed strong, punctate P2X1 receptor-like immunoreactivity in the majority of cells and faint, punctate staining with the anti-P2X2 and anti-P2X4 antibodies, whilst P2X5-like immunoreactivity was barely detectable and no P2X3, P2X6, and P2X7 receptor-like immunoreactivity was seen. No differences in P2X mRNA and protein expression were seen between small and large pulmonary arteries. In conclusion, the pharmacological properties and mRNA and protein expression profiles of P2X receptors in rat small and large pulmonary arteries are very similar. Thus P2X1 appears to be the predominant P2X subunit functionally expressed in smooth muscle cells of rat small and large pulmonary arteries.
Copyright © 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20868665     DOI: 10.1016/j.ejphar.2010.09.041

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  7 in total

1.  Anatomical and physiological factors contributing to chronic muscle pain.

Authors:  Nicholas S Gregory; Kathleen A Sluka
Journal:  Curr Top Behav Neurosci       Date:  2014

2.  A Ca²⁺-dependent chloride current and Ca²⁺ influx via Ca(v)1.2 ion channels play major roles in P2Y receptor-mediated pulmonary vasoconstriction.

Authors:  Callum Mitchell; Nawazish-i-Husain Syed; Alison M Gurney; Charles Kennedy
Journal:  Br J Pharmacol       Date:  2012-06       Impact factor: 8.739

3.  Characterisation of P2Y receptor subtypes mediating vasodilation and vasoconstriction of rat pulmonary artery using selective antagonists.

Authors:  Markie O Dales; Callum Mitchell; Alison M Gurney; Robert M Drummond; Charles Kennedy
Journal:  Purinergic Signal       Date:  2022-08-26       Impact factor: 3.950

4.  Using antibodies against P2Y and P2X receptors in purinergic signaling research.

Authors:  Dovrat Brass; Melanie R Grably; Noemi Bronstein-Sitton; Ofra Gohar; Alon Meir
Journal:  Purinergic Signal       Date:  2011-11-16       Impact factor: 3.765

5.  Role of P2X7R in the development and progression of pulmonary hypertension.

Authors:  Jie Yin; Shuling You; Haopeng Liu; Li Chen; Chengdong Zhang; Hesheng Hu; Mei Xue; Wenjuan Cheng; Ye Wang; Xinran Li; Yugen Shi; Nannan Li; Suhua Yan; Xiaolu Li
Journal:  Respir Res       Date:  2017-06-24

6.  Endothelial pannexin 1-TRPV4 channel signaling lowers pulmonary arterial pressure in mice.

Authors:  Zdravka Daneva; Matteo Ottolini; Yen Lin Chen; Eliska Klimentova; Maniselvan Kuppusamy; Soham A Shah; Richard D Minshall; Cheikh I Seye; Victor E Laubach; Brant E Isakson; Swapnil K Sonkusare
Journal:  Elife       Date:  2021-09-07       Impact factor: 8.140

Review 7.  Resolving the Ionotropic P2X4 Receptor Mystery Points Towards a New Therapeutic Target for Cardiovascular Diseases.

Authors:  Bruno Bragança; Paulo Correia-de-Sá
Journal:  Int J Mol Sci       Date:  2020-07-15       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.